Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD

Summary

The purpose of this Phase IIa study is to evaluate the safety, efficacy, and pharmacokinetics of JKN2304 Inhalation Solution in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The study is a multicenter, randomized, double-blind, placebo-controlled, and active-controlled (open-label) trial. Participants are randomized to receive JKN2304 (2 mg once daily or 2 mg twice daily), Placebo, or Formoterol Fumarate Inhalation Solution for a treatment period of 14 days.

Timeline

Start

2025-07-22

Primary completion

2025-09-25

Completion

2025-09-25

Drugs

Indications